Atlas Trials

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Clinical trial NCT00949351 · UNKNOWN

Trial details

NCT number
NCT00949351
Sponsor
Lerdsin General Hospital
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Type 2 Diabetes With Nephropathy
Start date
2009-09-01
Primary completion
2010-07-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.